## Answer
SGLT2 inhibitors are a class of medications used in the treatment of type 2 diabetes and have been shown to have renal protective effects. They work by inhibiting the sodium-glucose co-transporter 2 in the proximal tubules of the kidneys, which leads to increased glucose excretion in the urine and decreased blood glucose levels. 

Option A is incorrect. SGLT2 inhibitors have been shown to be safe and effective in patients with glomerular disease such as IgA nephropathy. They have been shown to slow the progression of kidney disease and reduce the risk of cardiovascular events in patients with type 2 diabetes and kidney disease.

Option B is also incorrect. While SGLT2 inhibitors can lower blood glucose levels, they do not typically cause hypoglycemia unless used in combination with other medications that can cause low blood sugar, such as insulin or sulfonylureas. Semaglutide is a GLP-1 receptor agonist, which also lowers blood glucose levels, but the risk of hypoglycemia is low unless used in combination with insulin or sulfonylureas.

Option C is incorrect. SGLT2 inhibitors should be temporarily discontinued at the time of surgery or during other periods of anticipated reduced oral intake, such as before a colonoscopy. This is because they can increase the risk of dehydration and ketoacidosis.

Option D is correct. SGLT2 inhibitors can cause a diuretic effect, which can potentially enhance the effects of other diuretics such as chlorthalidone. Therefore, the dose of chlorthalidone may need to be reduced with the initiation of an SGLT2 inhibitor to prevent excessive diuresis and dehydration.

Therefore, the answer is D. Chlorthalidone dose may need to be reduced with the initiation of an SGLT2 inhibitor.